Yes, Elevated White Blood Cell Counts Are Common in Polycythemia Vera
Yes, patients with polycythemia vera frequently have elevated white blood cell (WBC) counts—approximately 49% present with leukocytosis at diagnosis, and this finding is both a diagnostic feature and an important prognostic marker 1.
Diagnostic Context
The WHO 2016 diagnostic criteria for PV explicitly recognize leukocytosis as part of the disease presentation 2. While the hallmark of PV is erythrocytosis (elevated red blood cells), the bone marrow shows trilineage myeloproliferation—meaning increased production of red cells, white cells, and platelets 2. This explains why:
- 49% of patients have leukocytosis at diagnosis 1
- 53% have thrombocytosis 1
- The bone marrow demonstrates "age-adjusted hypercellularity and trilineage myeloproliferation" 2
Clinical Significance of Elevated WBC
Elevated WBC counts are not merely an incidental finding—they represent an independent risk factor for thrombotic events. The prospective REVEAL study (2,271 patients, median 44.7 months follow-up) demonstrated that:
- WBC >11 × 10⁹/L was associated with a 2.35-fold increased risk of thrombotic events (HR 2.35; 95% CI 1.598-3.465; P <0.0001) 3
- This association held true in both low-risk and high-risk PV patients 3
- Even when hematocrit was controlled at ≤45%, WBC >12 × 10⁹/L remained significantly associated with thrombosis (HR 1.95; 95% CI 1.066-3.554; P = 0.0300) 3
Treatment Implications
The recognition that elevated WBC counts independently increase thrombotic risk has important management implications:
- Traditional risk stratification focuses primarily on hematocrit control (<45%), but this may be insufficient 1
- Real-world data shows that 30.4% of patients on hydroxyurea still have elevated hematocrit after 1 year, and many continue treatment without adjustment despite suboptimal control 4
- Ruxolitinib demonstrates superior control of WBC counts: 54.2% of patients switching to ruxolitinib achieved WBC <11 × 10⁹/L after 1 year, compared to less effective control with hydroxyurea alone 4
Key Clinical Pitfalls
The most common error is focusing exclusively on hematocrit while ignoring WBC and platelet counts. The evidence strongly suggests that:
- Leukocytosis should be monitored as part of routine disease assessment
- WBC >11 × 10⁹/L warrants consideration of treatment intensification
- Patients with persistently elevated WBC despite standard therapy may benefit from alternative cytoreductive agents 3, 4
In summary: elevated WBC counts occur in approximately half of PV patients, represent an independent thrombotic risk factor, and should influence both risk stratification and treatment decisions 3, 1.